|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide: IARC Cancerbase No. 11 (Internet)International Agency
for Research on Cancer. Lyon, France: 2013 http://globocan.iarc.frAccessed. May 19–2014
|
|
2
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
MacFarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garofalo M, Quintavalle C, Romano G, Croce
CM and Condorelli G: miR221/222 in cancer: Their role in tumor
progression and response to therapy. Curr Mol Med. 12:27–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He S, Lai R, Chen D, Yan W, Zhang Z, Liu
Z, Ding X and Chen Y: Downregulation of miR-221 inhibits cell
migration and invasion through targeting methyl-CpG binding domain
protein 2 in human oral squamous cell carcinoma cells. Biomed Res
Int. 2015:7516722015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nassirpour R, Mehta PP, Baxi SM and Yin
MJ: miR-221 promotes tumorigenesis in human triple negative breast
cancer cells. PLoS One. 8:e621702013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei Y, Lai X, Yu S, Chen S, Ma Y, Zhang Y,
Li H, Zhu X, Yao L and Zhang J: Exosomal miR-221/222 enhances
tamoxifen resistance in recipient ER-positive breast cancer cells.
Breast Cancer Res Treat. 147:423–431. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz
B, Nieß H, Wang Y, Renner A, Mysliwietz J and Jauch KW: Antisense
inhibition of microRNA-21 and microRNA-221 in tumor-initiating
stem-like cells modulates tumorigenesis, metastasis, and
chemotherapy resistance in pancreatic cancer. Target Oncol.
10:535–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fornari F, Milazzo M, Galassi M, Callegari
E, Veronese A, Miyaaki H, Sabbioni S, Mantovani V, Marasco E,
Chieco P, et al: p53/mdm2 feedback loop sustains miR-221 expression
and dictates the response to anticancer treatments in
hepatocellular carcinoma. Mol Cancer Res. 12:203–216. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang CJ, Shen WG, Liu CJ, Chen YW, Lu HH,
Tsai MM and Lin SC: miR-221 and miR-222 expression increased the
growth and tumorigenesis of oral carcinoma cells. J Oral Pathol
Med. 40:560–566. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cruz-Munoz W and Khokha R: The role of
tissue inhibitors of metalloproteinases in tumorigenesis and
metastasis. Crit Rev Clin Lab Sci. 45:291–338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gan R, Yang Y, Yang X, Zhao L, Lu J and
Meng QH: Downregulation of miR-221/222 enhances sensitivity of
breast cancer cells to tamoxifen through upregulation of TIMP3.
Cancer Gene Ther. 21:290–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garofalo M, Di Leva G, Romano G, Nuovo G,
Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P,
et al: miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Starr TK, Scott PM, Marsh BM, Zhao L, Than
BL, O'Sullivan MG, Sarver AL, Dupuy AJ, Largaespada DA and Cormier
RT: A sleeping beauty transposon-mediated screen identifies murine
susceptibility genes for adenomatous polyposis coli (Apc)-dependent
intestinal tumorigenesis. Proc Natl Acad Sci USA. 108:5765–5770.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Than BL, Goos JA, Sarver AL, O'Sullivan
MG, Rod A, Starr TK, Fijneman RJ, Meijer GA, Zhao L, Zhang Y, et
al: The role of KCNQ1 in mouse and human gastrointestinal cancers.
Oncogene. 33:3861–3868. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2 (−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rong M, Chen G and Dang Y: Increased
miR-221 expression in hepatocellular carcinoma tissues and its role
in enhancing cell growth and inhibiting apoptosis in vitro. BMC
Cancer. 13:212013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiu D and Sun YC: Overexpression of
miR-221 inhibits proliferation and promotes apoptosis of human
astrocytoma cells. Int J Clin Exp Pathol. 8:4851–4856.
2015.PubMed/NCBI
|
|
19
|
Tanaka T, Tanaka M and Tanaka T: Oral
carcinogenesis and oral cancer chemoprevention: A review. Pathol
Res Int. 2011:4312462011. View Article : Google Scholar
|
|
20
|
Huang SH and O'Sullivan B: Oral cancer:
Current role of radiotherapy and chemotherapy. Med Oral Patol Oral
Cir Bucal. 18:e233–e240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gombos K, Horváth R, Szele E, Juhász K,
Gocze K, Somlai K, Pajkos G, Ember I and Olasz L: miRNA expression
profiles of oral squamous cell carcinomas. Anticancer Res.
33:1511–1517. 2013.PubMed/NCBI
|
|
22
|
Das AM, Seynhaeve AL, Rens JA, Vermeulen
CE, Koning GA, Eggermont AM and Ten Hagen TL: Differential TIMP3
expression affects tumor progression and angiogenesis in melanomas
through regulation of directionally persistent endothelial cell
migration. Angiogenesis. 17:163–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
